Direct-to-consumer genome testing: opportunities for pharmacogenomics research?
Pharmacogenomics 2010 May; 11(5): 651-5
This commentary examines the role that commercial providers of SNP-based genome-wide personalized risk profiles play in facilitating pharmacogenomics research. We first take a look at how personal genomics services, exemplified by the company 23andMe, communicate information on drug response to customers. We then discuss the most important benefits and issues we see arising with the idea of 'crowdsourcing' pharmacogenomics research via commercial genome-scan providers. We conclude with a brief vision for the future.
Permanent LinkFind Full Text at Georgetown University Library
Full Text from Publisher
Showing items related by title, author, creator and subject.
McGuire, Amy L; Evans, Barbara J; Caulfield, Timothy; Burke, Wylie (2010-10-08)
Blurring lines. The research activities of direct-to-consumer genetic testing companies raise questions about consumers as research subjects. Howard, Heidi C; Knoppers, Bartha Maria; Borry, Pascal (2010-08)
Health-related direct-to-consumer genetic testing: a review of companies' policies with regard to genetic testing in minors. Borry, Pascal; Howard, Heidi C; S?n?cal, Karine; Avard, Denise (2010-03)More and more companies are advertising and selling genetic tests directly to consumers. Considering the ethical, legal, and psychological concerns surrounding genetic testing in minors, a study of companies' websites was ...